There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI – Research Report), Pliant Therapeutics (PLRX – Research Report) and X4 Pharmaceuticals (XFOR – Research Report) with bullish sentiments.
Trevi Therapeutics (TRVI)
In a report released today, Leland Gershell from Oppenheimer initiated coverage with a Buy rating on Trevi Therapeutics and a price target of $9.00. The company’s shares closed last Friday at $1.39, close to its 52-week low of $1.26.
According to TipRanks.com, Gershell is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trevi Therapeutics with a $7.33 average price target, representing a 419.9% upside. In a report issued on November 2, JonesTrading also maintained a Buy rating on the stock with a $7.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Pliant Therapeutics (PLRX)
In a report released today, Yasmeen Rahimi from Piper Sandler initiated coverage with a Buy rating on Pliant Therapeutics and a price target of $40.00. The company’s shares closed last Friday at $14.52, close to its 52-week low of $13.04.
According to TipRanks.com, Rahimi is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pliant Therapeutics with a $47.80 average price target, implying a 206.0% upside from current levels. In a report issued on November 7, H.C. Wainwright also maintained a Buy rating on the stock with a $52.00 price target.
X4 Pharmaceuticals (XFOR)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on X4 Pharmaceuticals today and set a price target of $3.00. The company’s shares closed last Friday at $0.81, close to its 52-week low of $0.65.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for X4 Pharmaceuticals with a $3.00 average price target, which is a 278.9% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TRVI:
